Celcuity (CELC) stock was up more than 113% pre-bell Monday after the company said results from a phase 3 trial showed that a combination of gedatolisib, palbociclib, and fulvestrant reduced the risk of disease progression or death by 76% compared with fulvestrant alone in patients with locally advanced or metastatic breast cancer.
Mill City Ventures III (MCVT) shares were 61% higher, extending Friday's rally.
TruGolf (TRUG) stock was up 22% following a 5.8% loss on Friday.
22nd Century Group (XXII) shares were 23% higher, adding to a 4.1% increase in the previous session.